Please use this identifier to cite or link to this item: https://doi.org/10.1016/j.brainres.2007.12.024
DC FieldValue
dc.titleCombinatorial-approached neuroprotection using pan-caspase inhibitor and poly (ADP-ribose) polymerase (PARP) inhibitor following experimental stroke in rats; is there additional benefit?
dc.contributor.authorYap, E.
dc.contributor.authorNg, Y.-K.
dc.contributor.authorTan, W.-L.
dc.contributor.authorNg, I.
dc.date.accessioned2011-07-25T02:42:41Z
dc.date.available2011-07-25T02:42:41Z
dc.date.issued2008
dc.identifier.citationYap, E., Ng, Y.-K., Tan, W.-L., Ng, I. (2008). Combinatorial-approached neuroprotection using pan-caspase inhibitor and poly (ADP-ribose) polymerase (PARP) inhibitor following experimental stroke in rats; is there additional benefit?. Brain Research 1195 (C) : 130-138. ScholarBank@NUS Repository. https://doi.org/10.1016/j.brainres.2007.12.024
dc.identifier.issn00068993
dc.identifier.urihttp://scholarbank.nus.edu.sg/handle/10635/24311
dc.description.abstractEnergy requiring apoptosis and presumably unregulated necrosis are considered conceptually and morphologically distinct forms of cell death which have been initially identified as two exclusive pathways. However, several apoptotic characteristics have been observed in the necrotic core lesion in ischemia which led to the controversial theory that cell death advances via a number of hybrid pathways among a continuum between the two processes. ATP availability has been shown to influence the decision between apoptosis and necrosis. The aims of our study are 1) to determine if combined inhibitors administration of pan-caspase inhibitor Carbobenzoxy-Val-Ala-Asp-fluoromethylketone (z-VAD-fmk) and non-selective poly (ADP-ribose) polymerase (PARP) inhibitor 3-aminobenzamide (3-AB) can further reduce infarct volume compared to single modality of either inhibitor following ischemic insult, 2) to ascertain the pharmacological intervention up to 24 hour post-middle cerebral artery occlusion (MCAo), and 3) to correlate intracellular ATP level with infarct volume. Single modality treatment was optimised at 3 mg/kg z-VAD-fmk and 30 mg/kg 3-AB with infarct volume measured at 24.13% ± 3.89% and 26.98% ± 2.22% respectively, while untreated control group was determined at 45.97% ± 1.86%. Combined inhibitors treatment rendered further reduction in infarct volume, measuring 7.228% ± 1.988%, 21.02% ± 1.06%, 24.40% ± 2.12% at 30 min, 6 h, 24 h post-ischemia respectively. In conclusion, the combined inhibitors administration of both z-VAD-fmk and 3-AB show further increased in infarct volume reduction with our ischemic model up to the 24 hour post-MCAo. However, in our in vivo study, no correlation between intracellular ATP level and infarct size was established. © 2008 Elsevier B.V. All rights reserved.
dc.description.urihttp://libproxy1.nus.edu.sg/login?url=http://dx.doi.org/10.1016/j.brainres.2007.12.024
dc.sourceScopus
dc.subjectCaspase inhibitor
dc.subjectInfarct size
dc.subjectIntracellular ATP level
dc.subjectMiddle cerebral artery occlusion (MCAo)
dc.subjectPARP inhibitor
dc.typeArticle
dc.contributor.departmentANATOMY
dc.contributor.departmentDUKE-NUS GRADUATE MEDICAL SCHOOL S'PORE
dc.contributor.departmentNATIONAL UNIVERSITY MEDICAL INSTITUTES
dc.description.doi10.1016/j.brainres.2007.12.024
dc.description.sourcetitleBrain Research
dc.description.volume1195
dc.description.issueC
dc.description.page130-138
dc.identifier.isiut000254210500015
Appears in Collections:Staff Publications

Show simple item record
Files in This Item:
There are no files associated with this item.

SCOPUSTM   
Citations

18
checked on Oct 11, 2019

WEB OF SCIENCETM
Citations

16
checked on Oct 11, 2019

Page view(s)

177
checked on Oct 14, 2019

Google ScholarTM

Check

Altmetric


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.